Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women with Stage III Epithelial Ovarian Cancer: A Southwest Oncology Group Trial (SWOG-9326)
Authors:
- 1 August 2001
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 82 (2) , 317-322
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findingsObstetrics & Gynecology, 1999
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA)Gynecologic Oncology, 1993
- Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinomaGynecologic Oncology, 1992
- Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine)Cancer Treatment Reviews, 1991
- Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancerCancer Treatment Reviews, 1991
- The Role of Hexamethylmelamine in the Combination Chemotherapy of Advanced Ovarian CancerAmerican Journal of Clinical Oncology, 1990
- A Randomized Study of High-Dose versus Low-Dose cis-Platinum Combined with Cyclophosphamide in the Treatment of Advanced Ovarian CancerChemotherapy, 1989